US drug regulators have claimed recent law changes that enhance communication with pharmaceutical manufacturers helped prevent 140 potential drug shortages in 2013.
An increased trend in dealmaking for targeted drug delivery last year will continue to drive partnerships in 2014, according to a pharmaceutical partnering expert.
Recipharm says it has not decided whether to go public and list on the Swedish stock market after reports suggested it is preparing to join the exchange.
inVentiv Health has extended its partnership with NeuroVive Pharmaceutical AB to bring their drugs to treat acute cardiovascular and neurological conditions to market.
US Food and Drug Administration Commissioner Margaret Hamburg will travel to India from February 10-18 to strengthen the agency’s cooperation with Indian regulators at a time when India needs some direction.
SGS Life Science Services has expanded its laboratories in Wokingham, UK with a 7,000-sq ft extension which will house biologics stability and formulation testing.
The US Department of Justice is supplementing financial punishments for pharmaceutical companies violating FDA rules with corporate integrity agreements (CIAs), said the US Assistant Attorney General.
Covance has sold its high-complexity genomics laboratory to LabCorp as part of what an analyst says is decisive action to shed underperforming assets in its Early Development business.
Pharmaceutical services provider UDG Healthcare (formerly United Drug) announced today the integration of its sales, marketing and medical service divisions into one group, named Ashfield.
Shipments of chicken pox vaccines from a troubled Belgian facility should recommence in early Q2 2014, says GSK, though the root cause of the manufacturing issues are still unknown.
Demand for early phase services have increased but the industry is still “far away from the boom times of the early to mid 2000s,” according to an ISI analyst.
Novartis has confirmed that pharma jobs will be reallocated in 2014 in a continuation of the productivity drive that saved the firm $2.8bn (EUR2bn) last year.
A consortium of sponsors and CROs are beginning to participate in a survey that will not only assess their perceptions of quality but how those perceptions have stacked up over the years.
CordenPharma has received certification of Potent Compound Safety at a US plant and joins a growing list of drugmakers looking to assure HPAPI safety, according to SafeBridge Consultants.
Clarus Therapeutics has submitted to the FDA a testosterone replacement it claims overcomes the toxicity problems that have plagued other oral drugs like methyltestosterone.
Catalent has filed an initial public offering (IPO) with the SEC to raise $100m though this could reach upwards of $500m, according to one investment firm.
The Institute of Medicine is conducting a consensus study to recommend guiding principles and a framework for the responsible sharing of clinical trial data before a final report is released in December 2014.
Cambridge Isotope Laboratories (CIL) is working with Nexomics Biosciences to provide isotope-labeled proteins to nearly all of the world’s largest pharmaceutical companies.
Northwest Biotherapeutics has agreed with CMO Cognate Bioservices to begin a large-scale expansion of the manufacturing, storage, handling and distribution of its personalized immune therapies for solid tumor cancers.
Australia’s largest clinical CRO Novotech has expanded its clinical services with a new office in Johannesburg, South Africa to deal with increasing sponsor demand.
Actavis has announced plans to sell its stake in its Chinese subsidiary just days after telling investors the country is 'too risky' for new investments.
A French subsidiary of specialty ingredients firm Seppic has become the latest supplier certified under the Excipact quality scheme for drug excipients
Daiichi-Sankyo says ensuring API supply could be a problem at Ranbaxy’s US finished product sites after imports are banned from yet another of its Indian facilities.
The end of Lonza’s biosimilar joint venture with Teva will not affect manufacturing capacity, the firm says, as it reports a drop in overall revenue for 2013.
PharmaCell, the CMO that makes Provenge for Dendreon in Europe, has agreed to buy a facility from TiGenix to add capacity and a manufacturing contract for a second commercial product.
The need to improve efficiency and comply with regulatory and geographical demands is driving the third-party clinical payment industry, say Greenphire, CFS and Clinverse.
Higher earnings and improved margins did not impress investors in Lonza, which saw its share price tumble today after revealing that sales to the drug sector fell in 2013.
Increased in-house API production and manufacturing in India will lower the costs of Hospira’s injectables, the firm says, as it looks past current remediation efforts.
US FDA audits are a lot tougher than customer inspections according to CMO Regis, which has just passed two agency assessments with no 483 observations.
Eli Lilly is spending €75m ($102m) to meet latest global anti-counterfeiting regulations, its security experts said in an exclusive interview with in-Pharmatechnologist.com.
Novartis says it intends to shutter a New York manufacturing site due to reduced demand following the loss of exclusivity on its one-time topseller Diovan.
CEO Tom Pike emphasised Quintiles’ credentials as a Big Pharma collaborator and highlighted personalised medicines as a key driver for the CRO at an investment conference last week.
